In yesterday’s Wall Street session, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares traded at $20.76, down -3.58% from the previous session.
ARWR stock price is now 0.01% away from the 50-day moving average and -9.00% away from the 200-day moving average. The market capitalization of the company currently stands at $2.58B.
With the price target of $31, Goldman recently initiated with Neutral rating for Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR). On December 04, 2023, BofA Securities recently initiated its ‘Buy’ rating on the stock quoting a target price of $29, while ‘Citigroup’ rates the stock as ‘Neutral’
In other news, OLUKOTUN ADEOYE Y, Director bought 959 shares of the company’s stock on Jan 23 ’25. The stock was bought for $20,108 at an average price of $20.97. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06 ’25, Chief Discovery/Trans Medicine Hamilton James C sold 32,729 shares of the business’s stock. A total of $648,824 was realized by selling the stock at an average price of $19.82. This leaves the insider owning 272,122 shares of the company worth $5.65 million. A total of 6.90% of the company’s stock is owned by insiders.
During the past 12 months, Arrowhead Pharmaceuticals Inc has had a low of $17.05 and a high of $36.72. As of last week, the company has a debt-to-equity ratio of 4.59, a current ratio of 6.74, and a quick ratio of 6.74. The fifty day moving average price for ARWR is $20.7582 and a two-hundred day moving average price translates $22.813826 for the stock.
The latest earnings results from Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was released for 2024-06-30. The net profit margin was -16882.37% and return on equity was -262.48% for ARWR.
